- NASDAQ: MRNA has defied markets and advanced by nearly 3% on Wednesday.
- Moderna Inc. is set to extend gains as President Trump insists a vaccine will be ready shortly.
- AstraZeneca's temporary vaccine halt and Pfizer's enlargement of its trial put Moderna in a pole position.
Why is NASDAQ: MRNA moving higher? The main focus for investors has been the firm's advanced efforts to develop a COVID-19 vaccine. Moderna is busy running a final Phase 3 trial involving tens of thousands of people.
President Donald Trump has been pushing strongly for immunization to arrive in the US before the elections on November 3. He would like to paint a victorious picture, countering his mishandling of the virus so far 0 especially as America's death toll is nearing 200,000. Contrary to statements by Robert Redfield, head of the Center for Diseae Control, and Anthony Fauci, America's leading epidemiologist, he stated a vaccine is coming soon.
The president's words imply any pharmaceutical firm that announces positive results would receive emergency approval – and perhaps government funds to ramp up manufacturing.
Moderna is not alone in the race to register a full solution for the coronavirus pandemic. Pharma behemoth Pfizer is also conducting a Phase 3 trial in collaboration with Germany's BioNtech. That project asked to enlarge the number of participants from 30,000 to 44,000 without any clear explanations. Even if this move makes sense, it will likely slow Pfizer's attempt to reach a vaccine.
Another leading project comes from Britain's AstraZeneca. The project that involves the University of Oxford suffered a one-week pause after a participant fell ill. The trial later resumed, but the delay 0 and potentially others down the road – may put it behind.
All in all, Moderna is moving forward, and the mix of issues at the competition and a push from Uncle Sam put it in a pole position to win the race.
MRNA Stock Price
When a stock rises when the market falls – it is showing strength. That is what Moderna is experiencing, and for good reasons. The Massachusets-based pharma firm's stock rose by nearly $2 or 2.93% on Wednesday, closing at $48.84. It is changing hands at just above $70 in Thursday's pre-market trading.
Previously about the firm:
MRNA Stock Price: Moderna hits record high amid coronavirus vaccine progress, new test underway
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD holds below 1.0750 ahead of key US data
EUR/USD trades in a tight range below 1.0750 in the European session on Friday. The US Dollar struggles to gather strength ahead of key PCE Price Index data, the Fed's preferred gauge of inflation, and helps the pair hold its ground.
USD/JPY stays firm above 156.00 after BoJ Governor Ueda's comments
USD/JPY stays firm above 156.00 after surging above this level on the Bank of Japan's decision to leave the policy settings unchanged. BoJ Governor said weak Yen was not impacting prices but added that they will watch FX developments closely.
Gold price oscillates in a range as the focus remains glued to the US PCE Price Index
Gold price struggles to attract any meaningful buyers amid the emergence of fresh USD buying. Bets that the Fed will keep rates higher for longer amid sticky inflation help revive the USD demand.
Bitcoin Weekly Forecast: BTC’s next breakout could propel it to $80,000 Premium
Bitcoin’s recent price consolidation could be nearing its end as technical indicators and on-chain metrics suggest a potential upward breakout. However, this move would not be straightforward and could punish impatient investors.
US core PCE inflation set to signal firm price pressures as markets delay Federal Reserve rate cut bets
The core PCE Price Index, which excludes volatile food and energy prices, is seen as the more influential measure of inflation in terms of Fed positioning. The index is forecast to rise 0.3% on a monthly basis in March, matching February’s increase.